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Abstract
It is difficult to predict the risk of mortality in necrotizing enterocolitis (NEC). This study aimed at identifying risk factors 
for severe NEC (Bell stage III) and mortality in preterm children with NEC. In this multicenter retrospective study, we 
analyzed multiple data from 157 premature children with confirmed NEC in the period from January 2007 to October 2018. 
We performed univariate, multivariate, stepwise logistic regression, and receiver operator characteristics (ROC) analyses. 
We were able to demonstrate that low Apgar scores (notably at 1′ and 5′), low hemoglobin concentration (Hgb), and high 
lactate level at disease onset and during disease correlated with NEC severity and mortality (P < 0.05, respectively). Severe 
NEC was related to congenital heart disease (CHD — OR 2.6, CI95% 1.2–5.8, P 0.015) and patent ductus arteriosus (PDA 
— OR 3.3, CI95% 1.6–6.9, P 0.0012), whereas death was related to the presence of PDA (OR 5.5, CI95% 2.3–14, P < 0.001).
Conclusion: Low Apgar scores, low Hgb, high lactate levels, and the presence of CHD or PDA correlated with severe 
NEC or mortality in children with NEC.
What is Known:
• It remains difficult to predict which infant that suffers from necrotizing enterocolitis at risk of death.
• Several clinical and laboratory parameters tools to predict fatal outcome in NEC.
What is New:
• The following laboratory parameters were associated with the risk of death from NEC: Hemoglobin concentration, base excess and lactate 
level.
• The following clinical variables were associated with the risk of death from NEC: Apgar scores, as well as the presence of congenital heart 
disease and patent ductus arteriosus.
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Abbreviations
BW  birth weight
CHD  congenital heart disease
CI95  95% confidence interval
GA    gestational age  
Hgb    hemoglobin concentration  
INR  international normalized ratio
NA  not applicable
NEC  necrotizing enterocolitis  
PDA  patent ductus arteriosus  
PLT  platelet count
ROC  receiver operator characteristics  
WBC  white blood cell count
Introduction
Background
Necrotizing enterocolitis (NEC) is one of the main causes 
for morbidity and mortality in preterm neonates [1]. NEC 
survivors frequently suffer from neurodevelopmental 
impairment and gastrointestinal sequelae [2, 3]. To date, 
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however, the pathophysiology of NEC, as well as the factors 
associated with disease severity, has not been sufficiently 
investigated.
In previous studies, we were able to identify clinical 
variables (such as such as lactate level, platelet count, birth 
weight, and Bell stage), which allowed to predict mortal-
ity before surgery for NEC [4]. We were also able to show 
that the mortality rate of NEC patients increased in the 
presence of CHD or PDA [3, 5], but it is certainly worth 
noting that the correlation between CHD or PDA and the 
mortality rate of NEC is not without controversy. Pickard 
et al. and Bubberman et al., both described that outcomes 
in terms of mortality were not worse in NEC patients when 
they had additional CHD [6, 7].
Objectives
Our previous studies were carried out in monocentric 
settings, which only included small cohorts. Also, we 
wanted to include only premature infants since it is not 
clear whether NEC in term infants is comparable to NEC 
in preterm infants [8, 9]. In the present study, we have 
therefore chosen a multicenter retrospective study setting 
in order to identify the predictive potential of laboratory 
and clinical parameters, which might have an influence on 




This is a retrospective, multicentric study conducted in 
Swiss hospitals.
Setting and participants
We retrospectively collected data from three Swiss Hospi-
tals: The University’s Children Hospital, Bern; the Chil-
dren’s Hospital, Lucerne; and the Children’s Hospital of 
Eastern Switzerland, St. Gallen. We identified cases through 
an X-ray database query, including pre-term patients, with 
gestational age (GA) below 37 weeks, with confirmed NEC 
(Bell stage ≥ II [10]) below 4 months of postnatal age in the 
period from January 2007 to October 2018. We excluded 
patients with a postnatal age above 120 days or unconfirmed 
NEC. The data were extracted from medical records, includ-
ing radiographies.
Our study was approved by the local ethics committee 
(reference number: 2016–02066).
Variables
Our primary outcome variables were defined as mortality 
and disease severity (Bell stage III). We included additional 
variables, such as birth weight (BW, grams), GA (weeks/
days), the number of children per birth, assisted delivery, 
Apgar (1′, 5′, and 10′), CHD, PDA, congenital malforma-
tions or syndromes, age at diagnosis (days), Bell stage, con-
servative treatment only, NEC surgery, the number of surgi-
cal interventions (more than one surgical intervention due 
to NEC), re-NEC (defined as recurrence of NEC when the 
child was fully enterally nourished, or the parenteral nutri-
tion stopped), gender, year of birth, and various laboratory 
parameters before NEC (most recent parameter before dis-
ease onset, with a maximum gap of 1 week), at onset (at the 
time of the earliest therapeutic or diagnostic intervention), 
and during NEC (worst parameter before the antibiotics were 
stopped and the child refed). See complete Redcap Data Dic-
tionary Codebook in our supplementary information.
Data measurement
The data were collected in the RedCap database [11] and 
analyzed using a combined script written in Perl [12], 
Python (Python Software Foundation. Python Language 
Reference, version 2.7. http:// www. python. org), and R (R 
Core Team (2017), R Foundation for Statistical Computing, 
Vienna, Austria, https:// www.R- proje ct. org/).
Bias
We tried to minimize selection bias by training and coaching 
local investigators. Above, we performed quality surveys by 
checking completeness and accuracy of data entry. We used 
the X-ray and ultrasound database aiming at inclusion of all 
NEC patients.
Study size
Study duration but not the number of participants was 
defined before study onset.
Quantitative variables
Continuous variables were presented as median and inter-
quartile range (IQR). Discrete variables were approximated 
to binary variables (yes/no) and presented as the number of 
positive responses (“yes”) per total number of cases or con-
trols and the percentage of positive responses. When there 
was no data available for specific variables, we excluded 
these cases from our analysis. The number of patients hav- 
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ing been analyzed for respective variables is marked in the 
tables in the “N” column.
Statistical methods
We assessed statistical differences between survivors and 
non-survivors as well as between patients showing Bell stage 
III and Bell stage II. We used the Mann–Whitney-Wilcoxon 
test for continuous variables and the chi-square test for dis-
crete variables. To assess the influence of the various param-
eters on mortality and NEC stage III, we performed univari-
ate and multivariate regression analyses.
For those variables that correlated with mortality or 
severe NEC, we performed ROC [13] and thereby defined 
cutoffs for continuous variables. Thereafter, we converted 
these variables to binary values (defined as yes for continu-
ous values higher than cutoff, and “no” for values lower than 
cutoff).
Since multiple regression, including stepwise regression, 
did yield any significant model neither for the prediction of 
mortality nor for the development of NEC Bell stage III, 
we performed and reported univariate regression analysis 
to gain insight about the odds to die or to develop severe 
disease of the respective variables.
The results were considered statistically significant when 
the P value was less than 0.05.
Results
Participants
We included a total of 157 children, of whom 28 (17%) died 
and 44 (28%) showed NEC stage III.
Descriptive data
Median GA was 31 weeks 2 days (IQR 6.2). Median BW 
was 1405 g (IQR 960).
Outcome data
The significant differences in clinical variables between sur-
vivors and non-survivors are given in Table 1.
Overall differences in patient characteristics between sur-
vivors and non-survivors, as well as between infants with 
NEC stage II and stage III, are detailed in Table 1 of our 
supplementary information.
The significant differences in laboratory parameters 
between survivors and non-survivors are shown in Table 2.
The entire differences in laboratory parameters between 
survivors and non-survivors as well as between infants with 
NEC stage II and III are shown in Table 2 of our supplemen-
tary information.
The results of the univariate logistic regression model-
ling for the risk of development of NEC stage III, as well 
as for the risk of death, can be seen in our supplementary 
information, see Tables 3, 4, 5 and 7. The predictors in 
favor of mortality, including cutoffs on the basis of the 
ROC analysis, are shown in Table 3. Predictors of severe 
NEC are displayed in Table 8 in our supplementary infor-
mation. The types of CHD are given in table 10 in our 
supplementary information.
The results of the multivariate logistic regression are pre-
sented in our supplementary information — table 6 for the 
risk of severe NEC and table 9 for mortality, respectively. 
As stated above, no significant results were yielded from 
this analysis.
Main results
The values for BW, GA, Apgar values at 1, 5, and 10 min, 
as well as frequency of assisted delivery, were significantly 
different between survivors and non-survivors (P < 0.05, 
respectively, see Table 1, and Table 1 in our supplemen-
tary information).
Apgar scores below 6 at 1  min (OR 4, 1.7–11, P 
0.0033), under 7 at 5 min (OR 4.8, 2.1–12, P < 0.001) and 
under 8 at 10 min (OR 3.2, 1.3–8.2, P 0.011) as well as 
NEC surgery (OR 2.5, CI95% 1.1–5.8, P 0.032) correlated 
with an increased death rate (Table 3).
Table 1  Significant differences 
in patient characteristics 
between survivors and non-
survivors
Variable N Total Survivors Non-survivors P
n 157 129 28
Birth weight (g) (IQR) 157 1405 (960) 1480 (750) 855 (955) 0.0017
Gestational age (weeks/
days) (IQR)
157 31.2 (6.2) 32.0 (5.1) 27.0 (5.3)  < 0.001
Assisted delivery n (%) 156 133/156, 85% 107/128, 84% 26/28, 93% 0.093
Apgar 5 min (IQR) 153 8 (2) 8 (2) 6 (3)  < 0.001
Age at diagnosis (IQR) 157 9 (12) 8 (11) 11 (13.2) 0.039
Re-NEC n (%) 156 8/156, 5% 7/128, 5% 1/28, 4% 0.0025
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Furthermore, severe NEC correlated with mortality 
(OR 7.1, CI95% 3–18, P < 0.001), just like the presence 
of PDA (OR 5.5, CI95% 2.3–14, P < 0.001).
The following laboratory parameters were associated 
with an increased mortality rate: before disease onset: Hgb 
lower than 141 g/l (OR 3.9, 1.6–10, P 0.0042), minimum 
pH lower than 7.2 (OR 10, 2.3–56, P 0.0032); at disease 
onset: Hgb lower than 141 g/l (OR 3.6, 1.5–9.4, P 0.0061) 
and lactate over 3.8 mmol/l (OR 3.8, 1.4–10, P 0.0079); 
during the course of disease: Hgb below 113 g/l (OR 3.1, 
1.2–8.1, P 0.018) and lactate over 3.8 mmol/l (OR 3.4, 
1.3–8.8, P 0.011) (Table 3).
NEC stage III occurred more often in infants with a GA 
under 31 weeks and 2 days (OR 4.5, 2.1–10, P < 0.001). 
Table 2  Significant differences in laboratory parameters between survivors and non-survivors
Variable N Total Survivors Non-Survivors P
Minimum Hgb (g/l) before NEC onset (IQR) 77 132 (52) 142 (50) 114 (40.2) 0.035
Minimum Hgb (g/l) < 7 days before NEC onset (IQR) 132 144 (53.5) 153 (53) 127 (29) 0.0029
Hgb at disease presentation (g/l) (IQR) 149 140 (50) 146 (49.2) 121 (29)  < 0.001
Minimum Hgb during NEC (g/l) (IQR) 150 114 (35) 119 (37) 103 (19) 0.025
Minimum WBC (G/L) before NEC onset (IQR) 75 7.4 (5.85) 7.71 (5.6) 5.3 (3.78) 0.016
Maximum WBC (G/L) < 7 days before NEC onset (IQR) 120 13.8 (8.93) 13.2 (8.13) 15.6 (10.4) 0.049
Minimum PLT (G/l) before NEC onset (IQR) 74 164 (111) 169 (116) 97 (78) 0.015
Minimum PLT at disease presentation (G/l) (IQR) 148 214 (211) 222 (194) 116 (228) 0.011
Minimum PLT (G/l) during NEC (IQR) 150 157 (172) 174 (168) 57 (133) 0.0024
Minimum pH < 7 days before NEC onset (IQR) 70 7.26 (0.166) 7.26 (0.15) 7.14 (0.157) 0.016
Maximum CRP before NEC onset (IQR) 60 0 (8) 0 (7) 4 (32) 0.1
Maximum CRP (mg/l) < 7 days before NEC onset (IQR) 49 0 (6) 0 (5.25) 0 (24.5) 0.4
CRP at disease presentation (mg/L) (IQR) 135 7 (19.5) 7 (18) 11 (33.5) 0.1
Maximum CRP (mg/l) during NEC (IQR) 141 38 (97) 35 (103) 40.5 (66.5) 0.83
Maximum percentage of premature neutrophils at disease 
onset (%) (IQR)
109 23 (30) 21 (30.5) 35.5 (30.2) 0.054
Lactate at disease presentation (mmol/L) (IQR) 139 2.2 (2.1) 2.1 (1.8) 3.95 (4.38) 0.0078
Maximum Lactate (mmol/l) during NEC (IQR) 141 2.7 (2.5) 2.4 (2.1) 5.25 (5.85)  < 0.001
Base excess at disease presentation (mmol/L) (IQR) 136  − 2.4 (5.97)  − 2 (5.48)  − 7.9 (6.58)  < 0.001
Maximum base excess during NEC (mmol/L) (IQR) 140  − 3.9 (6.23)  − 3.1 (5.35)  − 10.8 (9.3)  < 0.001
Maximum INR during NEC (IQR) 38 1.34 (0.617) 1.2 (0.6) 1.7 (0.33) 0.024
Table 3  Predictors of mortality, univariate regression (NA not applicable)
ROC analysis Univariate regression
Value AUC cutoff Sensitivity Specificity PPV NPV OR CI95% P
Bell stage III NA NA NA NA NA NA 7.1 3–18  < 0.001
Gestational age (weeks/days) 0.7 29.0 0.71 0.7 0.34 0.92 5.8 2.4–15  < 0.001
Apgar 1 min 0.73 5.5 0.75 0.57 0.28 0.91 4 1.7–11 0.0033
Apgar 5 min 0.7 6.5 0.57 0.8 0.39 0.89 4.8 2.1–12  < 0.001
Apgar 10 min 0.7 7.5 0.61 0.78 0.39 0.9 3.2 1.3–8.2 0.011
PDA NA NA NA NA NA NA 5.5 2.3–14  < 0.001
Conservative treatment only NA NA NA NA NA NA 0.4 0.17–0.93 0.032
NEC surgery NA NA NA NA NA NA 2.5 1.1–5.8 0.032
Minimum Hb (g/l) < 7 days before NEC onset 0.7 141 0.78 0.6 0.29 0.93 3.9 1.6–10 0.0042
Minimum Hb during NEC (g/l) 0.64 113 0.76 0.56 0.26 0.92 3.1 1.2–8.1 0.018
Minimum pH < 7 days before NEC onset 0.75 7.2 0.67 0.84 0.38 0.94 10 2.3–56 0.0032
Hgb at disease presentation (g/l) 0.72 141 0.88 0.56 0.29 0.96 3.6 1.5–9.4 0.0061
Lactate at disease presentation (mmol/L) 0.68 3.8 0.55 0.83 0.38 0.91 3.8 1.4–10 0.0079
Maximum Lactate (mmol/l) during NEC 0.78 3.8 0.77 0.75 0.36 0.95 3.4 1.3–8.8 0.011
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Lower Apgar scores (less than 6 at 1 min, OR 2.4, 1.2–5.1, 
P 0.019 and less than 8 at 5 min, OR 3.2, 1.5–7, P 0.0033) 
could be related to severe NEC (table 7 of our supplemen-
tary information). In addition, the presence of CHD (OR 
2.6, CI95% 1.2–5.8, P 0.015) and PDA (OR 3.3, CI95% 
1.6–6.9, P 0.0012) increased the risk of severe NEC.
Finally, surgical treatment correlated significantly with 
the development of severe NEC (OR 61, CI95% 21–223, 
P < 0.001).
The laboratory parameters at disease onset that cor-
responded with NEC stage III included a proportion 
of immature neutrophils above 34% (OR 2.9, 1.2–7.4, 
P 0.025) and a lactate level over 2.6 mmol/l (OR 3.7, 
1.7–8.3, P 0.0012). During the disease, severe NEC cor-
related with a WBC higher than 22G/l (OR 4, 1.8–9.3, 
P < 0.001) and a lactate level above 3.8 mmol/l (OR 4.2, 
1.9–9.7, P < 0.001).
Discussion
Key results
The primary aim of this study was to gain insight into the 
factors influencing disease severity and mortality in prema-
ture children with NEC.
We were able to show that the presence of PDA tripled 
the risk of severe NEC, thus increasing the risk of death by 
a factor of five. CHD also tripled the risk of severe NEC.
Above that low Apgar scores, low Hgb, and high lactate 
levels correlated with severe NEC and mortality.
Limitations
Due to the retrospective study design, our study bears several 
limitations.
Patient treatment was at the discretion of the attending 
physician. We have found some minor differences of the 
clinical protocols concerning NEC relevant features like 
postnatal feeding, PDA management, or NEC treatment 
between the participating centers. However, due to copyright 
issues, we were not able to provide these protocols.
Heterogeneity of patient management also led to missing 
data, e.g., for laboratory parameters, which might thereby 
be biased.
Also, timing of the laboratory investigations was set at 
a relatively wide range of time and not reported in detail.
Using an X-ray and ultrasound database to identify NEC 
patients might have caused incomplete patient inclusion, 
such as patients with fulminant NEC.
In order to control such methodological problems in 
future studies, the differences in the NEC-relevant clinical 
protocols between the participating centers should be pre-
cisely documented, as we consider it very difficult to control 
the important NEC-relevant influencing factors in a uniform 
protocol for the management of premature infants.
Although we aimed to include a large number of patients 
by using a multicenter approach, we were not able to gain 
significant results by means of multiple regression analysis. 
We believe that statistically more robust knowledge about 
predictive factors for NEC could only be obtained from stud-
ies in larger patient populations.
Interpretation
These results confirm our previous finding that PDA seems 
to be a risk factors for mortality [5]. Furthermore, as sug-
gested by Carlo et al. [14], our results support the pathophys-
iological theory, according to which infants with PDA or 
CHD are at risk for NEC due to local intestinal ischemia. In 
contrast to our own previous findings, CHD was not corre-
lated with mortality. This is in accordance with the findings 
by others [6, 7] and warrants, as discussed above, evaluation 
in a larger cohort.
Our study supports other previous findings [15–18], 
according to which low BW and GA must be seen as risk 
factors for the development of severe NEC (Bell stage III).
Low Apgar scores (below 6 at 1 min and below 8 at 
5 min) could be related to more severe disease courses, 
which is consistent with findings of Stafford et al. [19], who 
were able to show that lower Apgar scores at 1 and 5 min 
can be associated with severe NEC.
It has already been shown that hyperlactatemia serves as 
predictor for poor outcomes in the treatment of critically ill 
children [20]. In 2003, Abubacker et al. demonstrated that 
pre-operative hyperlactatemia can possibly serve as predic-
tor in babies with NEC [21]. Our previous study confirmed 
this assumption [4]. As the results of this study confirm, lac-
tate values are clearly related to severe NEC, both at disease 
presentation and during progression of NEC.
To the best of our knowledge, our study is the first to 
show that there is a significant association between lac-
tate levels, disease severity, and mortality at disease onset, 
which, hopefully, will allow for a better and faster treatment 
of NEC in the future. The fact that we could extract data 
from a large multicenter patient group of preterm infants 
can be seen as strength of our study. We believe that our 
patient selection criteria as well as our data extraction meth-
ods reduced selection and observer bias.
Generalizability
Our study supports the current knowledge, that some influ- 
encing factors (such as low Apgar scores, congenital malfor- 
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mations, low Hgb, elevated lactate levels, and the presence 
of CHD or PDA,) might be helpful to predict the severity 
of NEC, and to adjust treatment measures for better disease 
outcomes. However, further studies, including prospective 
trials, are needed to confirm these variables as risk factors.
Supplementary Information The online version contains supplemen-
tary material available at https:// doi. org/ 10. 1007/ s00431- 021- 04266-x.
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